Morich bowling balls - Innogenetics, Adnagen, sign agreement for marketing of new oncology
Innogenetics, Adnagen, sign agreement for marketing of new oncology
CNBC - Frank Morich, CEO of Innogenetics, said his is “pleased with the feasibility results and believe that monitoring circulating tumour cells will provide physicians the means for improved cancer therapy”. No financial details were disclosed. frances
Brussels shares close lower; Delhaize leads the fallers UPDATE
CNBC - Outside the Bel 20, Innogenetics was 0.22 eur 3.41 pct lower at 6.23 as the market reacted negatively to news chief executive Frank Morich has stepped down, analysts said. Earlier, the biotech company said Christiaan De Wilde, who has been chief
Brussels shares TFN market data at 10.53 am; Suez leads
CNBC - Outside the Bel 20 -Innogenetics down 0.12 eur or 1.86 pct at 6.33 following resignation of CEO Frank Morich and appointment of replacement Christiaan De Wilde. KBC rating cut to ‘reduce’ from ‘accumulate’, target price 6 eur vs 8.50. -Kinepolis
Roundup: WVU women win at Penn State cross country event
Charleston Gazette - The teams will square off again in game three of the series at 5 p.m. today at Hawley Field. Admission is free. GALAXY LANES: Brian Antill rolled his eighth 300 game while Prince Moore rolled a 300 for the second time in the Galaxy Morich Men s
Innogenetics names Christiaan De Wilde CEO, replacing Frank Morich
CNBC - BRUSSELS (Thomson Financial) - Innogenetics NV has named Christiaan De Wilde its new chief executive, the Belgian biotech group said in a statement. De Wilde, who has been chief financial officer since last year, replaces Frank Morich, who is leaving
Shakers: People in the news
International Herald Tribune - Frank Morich, the chief executive of Innogenetics, the biotechnology company that halted development of a vaccine against liver disease last month, has resigned and will be temporarily replaced by Christiaan De Wilde. De Wilde will combine the
Add comment October 19th, 2007